Annual Report

Overview

The report highlights strong 2024 clinical data for evenamide in treatment-resistant and chronic schizophrenia, including sustained benefits and a favourable safety profile. It records Newron's December licensing agreement with EA Pharma for Japan and designated Asian territories, worth up to EUR 117 million, including EUR 44 million upfront. ESG disclosures report 22 FTE employees and 33% women on the Board at the end of 2024.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services